With Rinvoq and Skyrizi, these new anti-inflammatory drugs, taking over the throne from Humira, $AbbVie(ABBV)$ has increased its full-year profit forecast in 2024.AbbVie now expects adjusted earnings per share to range from $11.13 to $11.33, exceeding the previous high of $11.17 per share, according to a statement Friday.Abbvie shares fell 1.3% at the start of trading in New York. As of Thursday's close, the stock had risen 8%. The company has been working to fill the void left by Humira after it lost patent protection last year and cheaper biosimilars began eating into market share.Abbvie's new biologic drugs like Skyrizi and Rinvoq have been helping to offset the impact of declining Humira sales. And the company's recent deals in cancer and neur